Despite the benefit of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC) patients with EGFR mutation [1], acquired resistance to these therapies is a critical clinical problem. Here, EGFR is linked to non-small cell lung carcinoma.